

Vascular Endothelial Growth Factor in Ocular Neovascu Diabetic Retinopathy

DOI: 10.1002/(sici)1099-0895(199703)13:1<37::aid-dmr174>3.0.co;2-k

Citation Report

#	ARTICLE	IF	CITATIONS
1	Growth factor antagonists for the treatment of diabetic vascular complications. Expert Opinion on Investigational Drugs, 1997, 6, 1671-1684.	1.9	4
2	Advanced Glycation End Products in Age-related Macular Degeneration. JAMA Ophthalmology, 1998, 116, 1629.	2.6	172
3	Diabetic retinopathy: Some cellular, molecular and therapeutic considerations. Eye, 1999, 13, 497-523.	1.1	61
4	Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells. Circulation Research, 1999, 85, 699-706.	2.0	149
5	Molecular Mechanisms of Vascular Permeability in Diabetic Retinopathy. Seminars in Ophthalmology, 1999, 14, 240-248.	0.8	202
6	The purine nucleoside adenosine in retinal ischemia-reperfusion injury. Vision Research, 1999, 39, 2519-2535.	0.7	79
7	Expression of the VEGF Gene Family during Retinal Vaso-Obliteration and Hypoxia. Biochemical and Biophysical Research Communications, 1999, 262, 333-340.	1.0	65
8	Ocular manifestations of diabetes mellitus. Current Opinion in Ophthalmology, 1999, 10, 483-489.	1.3	48
9	VEGF release by retinal glia depends on both oxygen and glucose supply. NeuroReport, 2000, 11, 3533-3537.	0.6	75
10	The role of protein kinase C in the development of the complications of diabetes. Vitamins and Hormones, 2000, 60, 149-193.	0.7	54
11	The controls of microvascular survival. Cancer and Metastasis Reviews, 2000, 19, 75-81.	2.7	36
13	Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care, 2000, 23, 1375-1380.	4.3	47
14	Vascular Endothelial Growth Factor and Transforming Growth Factor- β 1 Regulate the Expression of Insulin-Like Growth Factor-Binding Protein-3, -4, and -5 in Large Vessel Endothelial Cells*. Endocrinology, 2000, 141, 2062-2067.	1.4	33
15	Insulin and Insulin-like Growth Factor-I Induce Vascular Endothelial Growth Factor mRNA Expression via Different Signaling Pathways. Journal of Biological Chemistry, 2000, 275, 21695-21702.	1.6	188
16	IDENTIFICATION OF POLYMORPHISMS WITHIN THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENE: CORRELATION WITH VARIATION IN VEGF PROTEIN PRODUCTION. Cytokine, 2000, 12, 1232-1235.	1.4	679
17	Endothelins, their receptors, and retinal vascular dysfunction in galactose-fed rats. Diabetes Research and Clinical Practice, 2000, 48, 75-85.	1.1	16
18	Altered Expression of Growth Factors and Cytokines in Keratoconus, Bullous Keratopathy and Diabetic Human Corneas. Experimental Eye Research, 2001, 73, 179-189.	1.2	60
19	Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Letters, 2001, 489, 270-276.	1.3	269

#	ARTICLE	IF	CITATIONS
20	Response of Experimental Retinal Neovascularization to Thiazolidinediones. <i>JAMA Ophthalmology</i> , 2001, 119, 709.	2.6	84
21	Hypoxia: modulation of endothelial cell proliferation by soluble factors released by retinal cells. <i>NeuroReport</i> , 2001, 12, 4103-4108.	0.6	30
22	Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. <i>Angiogenesis</i> , 2001, 4, 53-60.	3.7	54
23	Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5804-5808.	3.3	528
24	Systemically Expressed Soluble Tie2 Inhibits Intraocular Neovascularization. <i>Human Gene Therapy</i> , 2001, 12, 1311-1321.	1.4	67
25	Regulation of Vascular Endothelial Growth Factor Expression by Advanced Glycation End Products. <i>Journal of Biological Chemistry</i> , 2001, 276, 43836-43841.	1.6	178
26	Down-regulation of Vascular Endothelial Growth Factor and Up-regulation of Pigment Epithelium-derived Factor. <i>Journal of Biological Chemistry</i> , 2002, 277, 9492-9497.	1.6	119
27	Difference in Ischemic Regulation of Vascular Endothelial Growth Factor and Pigment Epithelium-Derived Factor in Brown Norway and Sprague Dawley Rats Contributing to Different Susceptibilities to Retinal Neovascularization. <i>Diabetes</i> , 2002, 51, 1218-1225.	0.3	91
28	Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. <i>Ophthalmology Clinics of North America</i> , 2002, 15, 69-79.	1.8	33
29	Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. <i>American Journal of Ophthalmology</i> , 2002, 134, 348-353.	1.7	223
30	Synthetic Peptides Interacting with the 67-kd Laminin Receptor Can Reduce Retinal Ischemia and Inhibit Hypoxia-Induced Retinal Neovascularization. <i>American Journal of Pathology</i> , 2002, 160, 307-313.	1.9	34
31	Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2579.	3.8	805
32	Immunolocalization and quantification of advanced glycation end products in retinal neovascular membranes and serum: A possible role in ocular neovascularization. <i>Current Eye Research</i> , 2002, 25, 139-145.	0.7	24
33	The Potential Role of PKC \hat{I}^2 in Diabetic Retinopathy and Macular Edema. <i>Survey of Ophthalmology</i> , 2002, 47, S263-S269.	1.7	148
34	Changing Times for the Management of Diabetic Retinopathy. <i>Survey of Ophthalmology</i> , 2002, 47, S238-S245.	1.7	19
35	Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 284-293.	1.2	62
36	Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. <i>Journal of Neurochemistry</i> , 2002, 80, 667-677.	2.1	257
37	Vascular endothelial growth factor (VEGF)-induced angiogenesis in herniated disc resorption. <i>Journal of Orthopaedic Research</i> , 2002, 20, 409-415.	1.2	119

#	ARTICLE	IF	CITATIONS
38	Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. <i>Angiogenesis</i> , 2002, 5, 181-190.	3.7	25
39	Vascular endothelial growth factors and angiogenesis in eye disease. <i>Progress in Retinal and Eye Research</i> , 2003, 22, 1-29.	7.3	829
40	Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. <i>European Journal of Pharmacology</i> , 2003, 458, 283-289.	1.7	135
41	Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 442-455.	1.7	253
42	IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism. See Editorial by Cooper and Thomas, p. 1584.. <i>Kidney International</i> , 2003, 63, 1249-1255.	2.6	22
43	Colocalization of Tie2, Angiopoietin 2 and Vascular Endothelial Growth Factor in Fibrovascular Membrane from Patients with Retinopathy of Prematurity. <i>Ophthalmic Research</i> , 2003, 35, 217-223.	1.0	36
44	Gene therapy for ocular neovascularization: a cure in sight. <i>Current Opinion in Genetics and Development</i> , 2003, 13, 317-322.	1.5	16
45	Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies. <i>Diabetes Care</i> , 2003, 26, 2653-2664.	4.3	695
46	Role of Vascular Endothelial Growth Factor and Placental Growth Factors During Retinal Vascular Development and Hyaloid Regression. , 2003, 44, 839.		70
47	Expression and Localization of Tenomodulin, a Transmembrane Type Chondromodulin-I-Related Angiogenesis Inhibitor, in Mouse Eyes. , 2003, 44, 1814.		66
48	Loss of pigment epithelium derived factor expression in glioma progression. <i>Journal of Clinical Pathology</i> , 2003, 56, 277-282.	1.0	74
49	Activation of Vascular Endothelial Growth Factor Receptor-1 Sustains Angiogenesis and Bcl-2 Expression Via the Phosphatidylinositol 3-Kinase Pathway in Endothelial Cells. <i>Diabetes</i> , 2003, 52, 2959-2968.	0.3	115
50	Characterization of Multiple Signaling Pathways of Insulin in the Regulation of Vascular Endothelial Growth Factor Expression in Vascular Cells and Angiogenesis. <i>Journal of Biological Chemistry</i> , 2003, 278, 31964-31971.	1.6	97
51	Rapid Insulin-Like Growth Factor (IGF)-Independent Effects of IGF Binding Protein-3 on Endothelial Cell Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 900-907.	1.8	75
52	Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. <i>Journal of Clinical Investigation</i> , 2003, 111, 1835-1842.	3.9	165
53	Vascular Endothelial Growth Factor and the Risk of Smoking-Related COPD. <i>Chest</i> , 2003, 124, 323-327.	0.4	39
54	Growth Factors in Proliferative Diabetic Retinopathy. <i>Experimental Diabetes Research</i> , 2003, 4, 287-301.	1.0	56
55	Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal Neovascularization. , 2003, 44, 3186.		296

#	ARTICLE	IF	CITATIONS
56	Involvement of Protein Kinase CK2 in Angiogenesis and Retinal Neovascularization. , 2004, 45, 4583.		73
57	Suppression of Corneal Neovascularization by PEDF Release from Human Amniotic Membranes. , 2004, 45, 1758.		102
58	VEGF164(165)as the Pathological Isoform: Differential Leukocyte and Endothelial Responses through VEGFR1 and VEGFR2. , 2004, 45, 368.		153
59	Diabetic Retinopathy. Diabetes Care, 2004, 27, 2540-2553.	4.3	575
60	Altered Insulin Signaling in Retinal Tissue in Diabetic States. Journal of Biological Chemistry, 2004, 279, 37997-38006.	1.6	84
61	Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes, Obesity and Metabolism, 2004, 6, 95-103.	2.2	33
62	Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. European Journal of Pharmacology, 2004, 498, 275-278.	1.7	49
63	The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opinion on Investigational Drugs, 2004, 13, 1275-1293.	1.9	148
64	Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Experimental Eye Research, 2004, 79, 465-476.	1.2	71
65	Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Current Opinion in Ophthalmology, 2004, 15, 211-220.	1.3	95
66	Pharmacotherapy for diabetic retinopathy. Current Opinion in Ophthalmology, 2004, 15, 508-518.	1.3	56
67	PKC/MAPK signaling suppression by retinal pericyte conditioned medium prevents retinal endothelial cell proliferation. Journal of Cellular Physiology, 2005, 203, 378-386.	2.0	16
68	EDB fibronectin and angiogenesis â€“ a novel mechanistic pathway. Angiogenesis, 2005, 8, 183-196.	3.7	95
69	A Single Local Injection of Recombinant VEGF Receptor 2 But Not of Tie2 Inhibits Retinal Neovascularization in the Mouse. Current Eye Research, 2005, 30, 249-257.	0.7	37
70	The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncology, 2005, 7, 452-464.	0.6	1,252
71	Angiogenic Pathways in Diabetic Retinopathy. New England Journal of Medicine, 2005, 353, 839-841.	13.9	169
72	Current and future pharmacological intervention for diabetic retinopathy. Expert Opinion on Emerging Drugs, 2005, 10, 441-455.	1.0	16
73	Differential Expression of Vascular Endothelial Growth Factor Implies the Limbal Origin of Pterygia. Ophthalmology, 2005, 112, 1023-1030.	2.5	58

#	ARTICLE	IF	CITATIONS
74	AAV-mediated gene transfer for retinal diseases. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1279-1294.	1.4	36
75	Anti-VEGF Therapies for Diseases of the Retina and Choroid. , 2006, , 309-339.		0
76	Inhibition of retinal neovascularization by soluble EphA2 receptor. <i>Experimental Eye Research</i> , 2006, 82, 664-673.	1.2	67
77	Vascular endothelial growth factor receptors: Molecular mechanisms of activation and therapeutic potentials. <i>Experimental Eye Research</i> , 2006, 83, 1005-1016.	1.2	86
78	Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. <i>Diabetologia</i> , 2006, 49, 1690-1701.	2.9	49
79	Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGFâ€™â€™VEGF receptor 2 binding in diabetic retinopathy. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 1-12.	1.1	238
80	Functional Characteristics of Connective Tissue Growth Factor on Vitreoretinal Cells. <i>Diabetes</i> , 2007, 56, 1421-1428.	0.3	47
81	Hypoxia-inducible factor expression in human RPE cells. <i>British Journal of Ophthalmology</i> , 2007, 91, 1406-1410.	2.1	68
82	The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 393-398.	1.0	30
83	Towards a rational approach to combination therapy for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2007, 91, 130-131.	2.1	4
84	Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. <i>Thrombosis and Haemostasis</i> , 2007, 97, 99-108.	1.8	95
85	Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. <i>Progress in Retinal and Eye Research</i> , 2007, 26, 1-37.	7.3	188
86	Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. <i>International Ophthalmology</i> , 2007, 27, 11-22.	0.6	42
87	Scutellarein inhibits hypoxia- and moderately-high glucose-induced proliferation and VEGF expression in human retinal endothelial cells. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 707-712.	2.8	39
88	Vascular endothelial growth factor in eye disease. <i>Progress in Retinal and Eye Research</i> , 2008, 27, 331-371.	7.3	607
89	Proliferative Diabetic Retinopathy. , 2008, , 29-65.		20
90	Attenuation of retinal endothelial cell migration and capillary morphogenesis in the absence of bcl-2. <i>American Journal of Physiology - Cell Physiology</i> , 2008, 294, C1521-C1530.	2.1	24
91	Aqueous Humor Levels of Vascular Endothelial Growth Factor in Retinitis Pigmentosa. , 2008, 49, 3499.		31

#	ARTICLE	IF	CITATIONS
92	Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Occlusion and Diabetic Macular Edema. <i>Journal of Korean Ophthalmological Society</i> , 2008, 49, 1275.	0.0	6
93	Decreased Hypoxia-Induced Neovascularization in Angiopoietin-2 Heterozygous Knockout Mouse through Reduced MMP Activity. <i>Cellular Physiology and Biochemistry</i> , 2009, 23, 277-284.	1.1	33
94	Neuroprotection for Diabetic Retinopathy. <i>Developments in Ophthalmology</i> , 2009, 44, 56-68.	0.1	31
95	Cysteine-rich 61, a Member of the CCN Family, as a Factor Involved in the Pathogenesis of Proliferative Diabetic Retinopathy. , 2009, 50, 3447.		35
96	Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. <i>Diabetologia</i> , 2009, 52, 359-361.	2.9	33
97	Müller cell-derived VEGF is a significant contributor to retinal neovascularization. <i>Journal of Pathology</i> , 2009, 219, 446-454.	2.1	196
98	The Pathologic Continuum of Diabetic Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, S35-S42.	1.2	370
99	Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: the role of mitochondrial reactive oxygen species. <i>Molecular and Cellular Biochemistry</i> , 2010, 343, 27-35.	1.4	62
100	Silver nano "A" trove for retinal therapies. <i>Journal of Controlled Release</i> , 2010, 145, 76-90.	4.8	98
101	Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. <i>Clinical and Experimental Ophthalmology</i> , 2010, 38, 875-884.	1.3	15
103	Temporal requirement of RPE-derived VEGF in the development of choroidal vasculature. <i>Journal of Neurochemistry</i> , 2010, 112, 1584-1592.	2.1	47
104	Inhibition of Reactive Oxygen Species by Lovastatin Downregulates Vascular Endothelial Growth Factor Expression and Ameliorates Blood-Retinal Barrier Breakdown in Mice. <i>Diabetes</i> , 2010, 59, 1528-1538.	0.3	183
105	Müller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage. <i>Diabetes</i> , 2010, 59, 2297-2305.	0.3	327
106	Ocular Retinopathies and Clinical Control of Angiogenesis. , 2010, , 27-65.		1
107	Ruboxistaurin, a PKC ² inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. <i>Experimental Eye Research</i> , 2010, 90, 137-145.	1.2	27
108	Leiomyoma and Vascular Endothelial Growth Factor Gene Polymorphisms: A Systematic Review. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2010, 49, 247-253.	0.5	13
109	VEGF, Ang-2 and SRIF associated abnormal postnatal development of the retinal capillary network in the Royal College of Surgeons rat. <i>Experimental Eye Research</i> , 2011, 92, 128-137.	1.2	9
110	Diabetic retinopathy " An update. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 99-111.	0.3	58

#	ARTICLE	IF	CITATIONS
111	MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. <i>Experimental and Molecular Pathology</i> , 2011, 91, 471-477.	0.9	98
112	Nonviral gene therapy for age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2011, 6, 81-93.	0.3	5
113	Identification of a Novel Inhibitor of the Canonical Wnt Pathway. <i>Molecular and Cellular Biology</i> , 2011, 31, 3038-3051.	1.1	114
114	Blood-Brain Barrier Breakdown and Blood-Brain Communication in Neurological and Psychiatric Diseases. <i>Cardiovascular Psychiatry and Neurology</i> , 2011, 2011, 1-2.	0.8	13
115	Vascular Pathology and Blood-Brain Barrier Disruption in Cognitive and Psychiatric Complications of Type 2 Diabetes Mellitus. <i>Cardiovascular Psychiatry and Neurology</i> , 2011, 2011, 1-10.	0.8	78
116	Preconditioning with Endoplasmic Reticulum Stress Mitigates Retinal Endothelial Inflammation via Activation of X-box Binding Protein 1. <i>Journal of Biological Chemistry</i> , 2011, 286, 4912-4921.	1.6	107
117	Increased Expression and Activity of 12-Lipoxygenase in Oxygen-Induced Ischemic Retinopathy and Proliferative Diabetic Retinopathy. <i>Diabetes</i> , 2011, 60, 614-624.	0.3	76
118	A PEDF-Derived Peptide Inhibits Retinal Neovascularization and Blocks Mobilization of Bone Marrow-Derived Endothelial Progenitor Cells. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-11.	3.8	40
119	Tenomodulin Inhibits Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy. <i>International Journal of Molecular Sciences</i> , 2012, 13, 15373-15386.	1.8	10
120	Angiofibrotic Response to Vascular Endothelial Growth Factor Inhibition in Diabetic Retinal Detachment. <i>JAMA Ophthalmology</i> , 2012, 130, 1127.	2.6	47
121	Therapeutic Potential of a Monoclonal Antibody Blocking the Wnt Pathway in Diabetic Retinopathy. <i>Diabetes</i> , 2012, 61, 2948-2957.	0.3	76
122	Ranibizumab in patients with dense cataract and proliferative diabetic retinopathy with rubeosis. <i>Oman Journal of Ophthalmology</i> , 2012, 5, 161.	0.2	10
123	The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	74
124	Association of VEGF gene polymorphisms with advanced retinopathy of prematurity: a meta-analysis. <i>Molecular Biology Reports</i> , 2012, 39, 10731-10737.	1.0	11
125	Expression of promyelocytic leukemia protein and vascular endothelial growth factor in aqueous humor and vitreous fluid in patients with proliferative diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, e9-e11.	1.1	5
126	Prevention and management of diabetic retinopathy in STZ diabetic rats by <i>Tinospora cordifolia</i> and its molecular mechanisms. <i>Food and Chemical Toxicology</i> , 2012, 50, 3126-3132.	1.8	52
127	Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. <i>Clinical Ophthalmology</i> , 2012, 6, 1175.	0.9	61
128	Retinal Not Systemic Oxidative and Inflammatory Stress Correlated with VEGF Expression in Rodent Models of Insulin Resistance and Diabetes. , 2012, 53, 8424.		46

#	ARTICLE	IF	CITATIONS
129	Investigation of Ocular Neovascularization-Related Genes and Oxidative Stress in Diabetic Rat Eye Tissues After Resveratrol Treatment. <i>Journal of Medicinal Food</i> , 2012, 15, 391-398.	0.8	33
130	Inflammation and Angiogenesis in Diabetic Retinopathy. , 0, , .		0
131	ERK1/2 Signaling Pathway in the Release of VEGF from Müller Cells in Diabetes. , 2012, 53, 3481.		34
132	Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. <i>Angiogenesis</i> , 2012, 15, 171-185.	3.7	838
133	Regulation of Endothelial Progenitor Cell Release by Wnt Signaling in Bone Marrow. , 2013, 54, 7386.		13
134	Nitrosative Stress Plays an Important Role in Wnt Pathway Activation in Diabetic Retinopathy. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 1141-1153.	2.5	51
135	Neuroprotective Effects of Cilostazol on Retinal Ganglion Cell Damage in Diabetic Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 457-463.	1.3	20
137	Hypoxia-induced expression of VEGF splice variants and protein in four retinal cell types. <i>Experimental Eye Research</i> , 2013, 116, 240-246.	1.2	24
138	Study In Vivo Intraocular Biocompatibility of In Situ Gelation Hydrogels: Poly(2-Ethyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 427 Td (Oxaz Pluronic F127. <i>PLoS ONE</i> , 2013, 8, e67495.	1.1	27
139	Caspase-14 Expression Impairs Retinal Pigment Epithelium Barrier Function: Potential Role in Diabetic Macular Edema. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	25
140	Nerve growth factor in diabetic retinopathy: beyond neurons. <i>Expert Review of Ophthalmology</i> , 2014, 9, 99-107.	0.3	48
141	Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 699-706.	1.1	36
142	Potential Therapeutic Effects of Baicalein, Baicalin, and Wogonin in Ocular Disorders. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 605-614.	0.6	60
143	Scutellarin Inhibits High Glucose-induced and Hypoxia-mimetic Agent-induced Angiogenic Effects in Human Retinal Endothelial Cells Through Reactive Oxygen Species/Hypoxia-inducible Factor-1 α /Vascular Endothelial Growth Factor Pathway. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 218-227.	0.8	37
144	Sustained inhibition of neovascularization in vldlr ^{-/-} mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38/JNK-NF- κ B pathway. <i>Biomaterials</i> , 2014, 35, 249-258.	5.7	79
145	The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 473-482.	3.2	120
146	Association of monocyte chemoattractant protein-1 (MCP-1)2518A/G polymorphism with proliferative diabetic retinopathy in northern Chinese type 2 diabetes. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1921-1926.	1.0	22
147	The role of angiostatins in diabetic complications. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2014, 8, 94-107.	0.2	3

#	ARTICLE	IF	CITATIONS
148	Retinal Microangiopathy in a Mouse Model of Inducible Mural Cell Loss. <i>American Journal of Pathology</i> , 2014, 184, 2618-2626.	1.9	26
149	Angiogenesis and Eye Disease. <i>Annual Review of Vision Science</i> , 2015, 1, 155-184.	2.3	41
150	Domain I-IV of Î2-glycoprotein I inhibits advanced glycation end product-induced angiogenesis by down-regulating vascular endothelial growth factor 2 signaling. <i>Molecular Medicine Reports</i> , 2015, 11, 2167-2172.	1.1	6
151	Imbalance of the Nerve Growth Factor and Its Precursor as a Potential Biomarker for Diabetic Retinopathy. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	46
152	Primary Retinal Cultures as a Tool for Modeling Diabetic Retinopathy: An Overview. <i>BioMed Research International</i> , 2015, 2015, 1-16.	0.9	20
153	Association between a vascular endothelial growth factor gene polymorphism (rs2146323) and diabetic retinopathy: a meta-analysis. <i>BMC Ophthalmology</i> , 2015, 15, 163.	0.6	20
154	Dystrophin Dp71 gene deletion induces retinal vascular inflammation and capillary degeneration. <i>Human Molecular Genetics</i> , 2015, 24, 3939-3947.	1.4	27
155	Current nanotechnology approaches for the treatment and management of diabetic retinopathy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 95, 307-322.	2.0	72
156	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
157	Incretin-Based Therapy for Prevention of Diabetic Vascular Complications. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-12.	1.0	26
158	Cnidium officinale extract and butylidenephthalide inhibits retinal neovascularization in vitro and in vivo. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 231.	3.7	27
159	Occludin S490 Phosphorylation Regulates Vascular Endothelial Growth Factor-Induced Retinal Neovascularization. <i>American Journal of Pathology</i> , 2016, 186, 2486-2499.	1.9	37
160	Oxidative stress in retinal pigment epithelium cells increases exosome secretion and promotes angiogenesis in endothelial cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1457-1466.	1.6	180
161	Predictors of Proliferative diabetic retinopathy among patients with type 2 diabetes mellitus in Malaysia as detected by fundus photography. <i>Journal of Taibah University Medical Sciences</i> , 2016, 11, 353-358.	0.5	2
162	Presence and Risk Factors for Glaucoma in Patients with Diabetes. <i>Current Diabetes Reports</i> , 2016, 16, 124.	1.7	90
163	Tat PTD-Endostatin-RGD: A novel protein with anti-angiogenesis effect in retina via eye drops. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 2137-2147.	1.1	20
164	S100A4 gene silencing in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via down-regulation of CREB expression. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 97-108.	1.0	6
165	Impact of Diabetic Complications on Balance and Falls: Contribution of the Vestibular System. <i>Physical Therapy</i> , 2016, 96, 400-409.	1.1	69

#	ARTICLE	IF	CITATIONS
167	Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits. <i>Current Eye Research</i> , 2017, 42, 315-322.	0.7	8
168	The Diabetic Retina: Anatomy and Pathophysiology. , 2017, , 29-72.		0
169	Proliferative diabetic retinopathy characterization based on the spatial organization of vascular junctions in fundus images. , 2017, , .		2
170	Effect of cilostazol in treating diabetes-associated microvascular complications. <i>Endocrine</i> , 2017, 56, 240-244.	1.1	31
171	Modeling angiogenesis with micro- and nanotechnology. <i>Lab on A Chip</i> , 2017, 17, 4186-4219.	3.1	32
172	Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling. <i>Vascular Pharmacology</i> , 2017, 90, 19-26.	1.0	17
173	Therapeutic Effect of Cilostazol Ophthalmic Nanodispersions on Retinal Dysfunction in Streptozotocin-Induced Diabetic Rats. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1971.	1.8	20
174	Mitochondrial transcription factor A protects human retinal endothelial cell injury induced by hypoxia. <i>Tropical Journal of Pharmaceutical Research</i> , 2017, 16, 1259.	0.2	1
175	Effects of Histone Deacetylase Inhibitor (Valproic Acid) on the Expression of Hypoxia-inducible Factor-1 Alpha in Human Retinal MÄ¼ller Cells. <i>Korean Journal of Ophthalmology: KJO</i> , 2017, 31, 80.	0.5	7
176	Occipital bloodâ€brain barrier permeability is an independent predictor of visual outcome in type 2 diabetes, irrespective of the retinal barrier: A longitudinal study. <i>Journal of Neuroendocrinology</i> , 2018, 30, e12566.	1.2	6
177	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 127-146.	7.3	205
178	Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients. <i>Ophthalmic Research</i> , 2018, 60, 250-257.	1.0	12
179	<i>CACNB2</i> Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 2165-2174.	0.3	16
180	NEW PROPOSAL FOR THE PATHOPHYSIOLOGY OF TYPE 3 NEOVASCULARIZATION AS BASED ON MULTIMODAL IMAGING FINDINGS. <i>Retina</i> , 2019, 39, 1451-1464.	1.0	27
181	Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction. <i>Frontiers in Pharmacology</i> , 2019, 10, 1363.	1.6	57
182	Scutellarin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF/ERK/FAK/Src Pathway Signaling. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-17.	1.0	42
183	APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION. <i>Retina</i> , 2019, 39, 265-273.	1.0	18
184	TIME COURSE OF CHANGES IN OPTIC DISK NEOVASCULARIZATION AFTER A SINGLE INTRAVITREAL BEVACIZUMAB INJECTION. <i>Retina</i> , 2019, 39, 1149-1153.	1.0	11

#	ARTICLE	IF	CITATIONS
185	PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020, 40, 643-647.	1.0	38
186	Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy. <i>Chinese Medical Journal</i> , 2020, , 664-669.	0.9	16
187	Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 409-417.	1.8	26
188	TNF α signaling regulates RUNX1 function in endothelial cells. <i>FASEB Journal</i> , 2021, 35, e21155.	0.2	28
189	PRODUCTION AND APPLICATION OF ANGIOSTATINS FOR THE TREATMENT OF OCULAR NEOVASCULAR DISEASES. <i>Biotechnologia Acta</i> , 2021, 14, 5-24.	0.3	1
190	Retinal Molecular Changes Are Associated with Neuroinflammation and Loss of RGCs in an Experimental Model of Glaucoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2066.	1.8	26
191	Astaxanthin mediated regulation of VEGF through HIF1 α and XBP1 signaling pathway: An insight from ARPE-19 cell and streptozotocin mediated diabetic rat model. <i>Experimental Eye Research</i> , 2021, 206, 108555.	1.2	15
192	VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6590.	1.8	6
193	MicroRNA-126 inhibits pathological retinal neovascularization via suppressing vascular endothelial growth factor expression in a rat model of retinopathy of prematurity. <i>European Journal of Pharmacology</i> , 2021, 900, 174035.	1.7	4
194	Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. <i>Pharmaceutics</i> , 2021, 13, 1102.	2.0	8
195	Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. <i>BMC Ophthalmology</i> , 2021, 21, 300.	0.6	13
196	Visual Outcomes in Eyes with Neovascular Glaucoma and Anterior Segment Neovascularization Without Glaucoma. <i>American Journal of Ophthalmology</i> , 2021, , .	1.7	8
198	Pathophysiology of Diabetic Retinopathy. , 2010, , 1-30.		10
199	Endothelins in the Microvasculature and Heart in Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2001, 498, 97-108.	0.8	3
201	Proliferative Diabetic Retinopathy. , 2006, , 1285-1322.		7
202	Neovascular Glaucoma. , 2008, , 2689-2712.		4
204	Complications of Diabetes Mellitus. , 2011, , 1462-1551.		8
205	Molecular biology of choroidal neovascularization. <i>Ophthalmology Clinics of North America</i> , 2006, 19, 323-34.	1.8	39

#	ARTICLE	IF	CITATIONS
206	Vascular endothelial growth factor: a neurovascular target in neurological diseases. <i>Nature Reviews Neurology</i> , 2016, 12, 439-454.	4.9	252
207	Molecular mechanisms of growth factor action in diabetic retinopathy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 1999, 6, 146-156.	0.6	7
208	Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. <i>Journal of Clinical Investigation</i> , 2003, 111, 1835-1842.	3.9	106
209	Diabetic Retinopathy and Public Health. , 2009, , .		2
210	Inhibition of Oxygen-Induced Ischemic Retinal Neovascularization with Adenoviral 15-Lipoxygenase-1 Gene Transfer via Up-Regulation of PPAR- γ and Down-Regulation of VEGFR-2 Expression. <i>PLoS ONE</i> , 2014, 9, e85824.	1.1	14
211	Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization. <i>PLoS ONE</i> , 2014, 9, e94205.	1.1	37
213	Cellular and Molecular Mechanisms of Retinal Ganglion Cell Death in Hypoxic-Ischemic Injuries. <i>Journal of Neurology and Experimental Neuroscience</i> , 0, , .	0.2	4
215	Diabetic Retinopathy: Understanding Pathologic Angiogenesis and Exploring its Treatment Options. <i>The Open Circulation & Vascular Journal</i> , 2012, 3, 30-42.	0.4	5
216	Curcumin Metabolite Tetrahydrocurcumin in the Treatment of Eye Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 212.	1.8	23
217	Retinal proteomic evaluation of rats following streptozotocin injection using shotgun proteomics. <i>Molecular Medicine Reports</i> , 2020, 21, 379-386.	1.1	3
218	Prognostic Factors for Long Term Visual Acuity Outcome after Ranibizumab Therapy in Patients with Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical & Experimental Ophthalmology</i> , 2013, 04, .	0.1	5
219	Ginsenoside-Rb1 Induces ARPE-19 Proliferation and Reduces VEGF Release. <i>ISRN Ophthalmology</i> , 2011, 2011, 1-6.	1.7	13
220	Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy. <i>PLoS ONE</i> , 2021, 16, e0258415.	1.1	2
221	New Insights into the Molecular Mechanisms of Vascular Permeability in Diabetes. , 2002, , 23-33.		0
222	Design of Clinical Trials for Anti-Angiogenics. , 2002, , 527-545.		1
223	Correcting anemia slows renal disease progression. , 2002, , 1-7.		0
225	Diabetic Retinopathy and Ocular Complications. , 2007, , 251-262.		0
226	Pericytes, the Mural Cells of the Microvascular System. , 2008, , 45-53.		3

#	ARTICLE	IF	CITATIONS
230	SEVERITY OF DIABETIC RETINOPATHY IN RELATION WITH HEMOGLOBIN A1c AND SERUM LIPIDS. Journal of Evolution of Medical and Dental Sciences, 2013, 2, 2011-2023.	0.1	1
231	Resorption mechanisms related with neo-vascularization for the lumbar disc herniation. Abant Medical Journal, 2015, 4, 89-94.	0.0	1
233	Effect of endothelial progenitor cells derived from human umbilical cord blood on oxygen-induced retinopathy in mice by intravitreal transplantation. International Journal of Ophthalmology, 2016, 9, 1578-1583.	0.5	5
235	Chemical Modification of Ginsenoside on Cell Viability and Cytokine Secretion. Current Aging Science, 2017, 10, 68-75.	0.4	0
238	Neovascular Glaucoma. , 2020, , 1-39.		0
239	Potential of Human Neural Precursor Cells in Diabetic Retinopathy Therapeutics – Preclinical Model. Current Eye Research, 2022, 47, 450-460.	0.7	0
240	Thrombospondin. , 2006, , 233-255.		0
241	Vascular endothelial growth factor and ocular neovascularization. American Journal of Pathology, 1997, 151, 13-23.	1.9	89
242	Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Molecular Vision, 2007, 13, 133-41.	1.1	25
243	Inhibition of retinal neovascularization by siRNA targeting VEGF(165). Molecular Vision, 2008, 14, 1965-73.	1.1	22
244	Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. Clinical Ophthalmology, 2007, 1, 383-91.	0.9	21
245	Overexpression of 15-lipoxygenase-1 in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via downregulation of vascular endothelial growth factor-A expression. Molecular Vision, 2012, 18, 2847-59.	1.1	8
246	The effects of small interfering RNA-targeting tissue factor on an in vitro model of neovascularization. Molecular Vision, 2013, 19, 1296-303.	1.1	9
247	Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy. Molecular Vision, 2015, 21, 673-87.	1.1	10
249	Heparanase mediates vascular endothelial growth factor gene transcription in high-glucose human retinal microvascular endothelial cells. Molecular Vision, 2017, 23, 579-587.	1.1	6
250	Differences in activation of intracellular signaling in primary human retinal endothelial cells between isoforms of VEGFA 165. Molecular Vision, 2021, 27, 191-205.	1.1	1
251	Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy. Graefes Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1899-1906.	1.0	2
252	Curcumin in Retinal Diseases: A Comprehensive Review from Bench to Bedside. International Journal of Molecular Sciences, 2022, 23, 3557.	1.8	6

#	ARTICLE	IF	CITATIONS
253	VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. <i>Annals of Medicine</i> , 2022, 54, 1089-1111.	1.5	37
254	Nonproliferative and Proliferative Diabetic Retinopathy. , 2022, , 2955-2993.		1
255	Neovascular Glaucoma. , 2022, , 1769-1806.		0
256	Towards the Development of Longer and More Efficacious Therapies for Wet and Dry Age-related Macular Degeneration. , 2022, 16, 30.		0
258	Nomogram for prediction of diabetic retinopathy in patients with type 2 diabetes mellitus: A retrospective study. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108313.	1.2	5